Kevin Dew

Kevin Dew

Auto-generated profile, based on publicly available information

Kevin Dew

Te Herenga Waka – Victoria University of Wellington

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Social Science & Medicine
Verified
Journal Article
Closed access
KDKevin Dew
Kevin Dew
VKVera Keefe
Vera Keefe
KSKeitha Small
Keitha Small

7 January 2010 in Journal of Epidemiology and Community Health
Verified
Journal Article
Closed access
PDF file
SHSarah Hill
Sarah Hill
DSDiana Sarfati
Diana Sarfati
TBTony Blakely
Tony Blakely
BRBridget Robson
Bridget Robson
GPGordon Purdie
Gordon Purdie
IKIchiro Kawachi
Ichiro Kawachi
Background Ethnic disparities in cancer survival have been documented in many populations and cancer types. The causes of these inequalities are not well understood but may include disease and patient characteristics, treatment differences and health service factors. Survival was compared in a cohort of Maori (Indigenous) and non-Maori New Zealanders with colon cancer, and the contribution of demographics, disease characteristics, patient comorbidity, treatment and healthcare factors to survival disparities was assessed. Methods Maori patients diagnosed as having colon cancer between 1996 and 2003 were identified from the New Zealand Cancer Registry and compared with a randomly selected sample of non-Maori patients. Clinical and outcome data were obtained from medical records, pathology reports and the national mortality database. Cancer-specific survival was examined using Kaplan–Meier survival curves and Cox hazards modelling with multivariable adjustment. Results 301 Maori and 328 non-Maori patients with colon cancer were compared. Maori had a significantly poorer cancer survival than non-Maori (hazard ratio (HR)=1.33, 95% CI 1.03 to 1.71) that was not explained by demographic or disease characteristics. The most important factors contributing to poorer survival in Maori were patient comorbidity and markers of healthcare access, each of which accounted for around a third of the survival disparity. The final model accounted for almost all the survival disparity between Maori and non-Maori patients (HR=1.07, 95% CI 0.77 to 1.47). Conclusion Higher patient comorbidity and poorer access and quality of cancer care are both important explanations for worse survival in Maori compared with non-Maori New Zealanders with colon cancer.

20 April 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DSDiana Sarfati
Diana Sarfati
SHSarah Hill
Sarah Hill
TBTony Blakely
Tony Blakely
BRBridget Robson
Bridget Robson
GPGordon Purdie
Gordon Purdie
KDKevin Dew
Kevin Dew
Comorbidity has a well documented detrimental effect on cancer survival. However it is difficult to disentangle the direct effects of comorbidity on survival from indirect effects via the influence of comorbidity on treatment choice. This study aimed to assess the impact of comorbidity on colon cancer patient survival, the effect of comorbidity on treatment choices for these patients, and the impact of this on survival among those with comorbidity.

1 October 2007 in Australian and New Zealand Journal of Public Health
Verified
Journal Article
Closed access
PDF file
KDKevin Dew
Kevin Dew

1 June 2011 in Social Science & Medicine
Verified
Journal Article
Closed access
VIVivienne Ivory
Vivienne Ivory
SCSunny Collings
Sunny Collings
TBTony Blakely
Tony Blakely
KDKevin Dew
Kevin Dew

21 April 2010 in Cancer
Verified
Journal Article
Open access
PDF file
SHSarah Hill
Sarah Hill
DSDiana Sarfati
Diana Sarfati
TBTony Blakely
Tony Blakely
BRBridget Robson
Bridget Robson
GPGordon Purdie
Gordon Purdie
IKIchiro Kawachi
Ichiro Kawachi
BACKGROUND: Racial and ethnic inequalities in colon cancer treatment have been reported in the United States but not elsewhere. The authors of this report compared cancer treatment in a nationally representative cohort of Maori (indigenous) and non‐Maori New Zealanders with colon cancer.METHODS: On the basis of cancer registry data, 301 Maori patients and 329 randomly selected non‐Maori patients were identified who were diagnosed with colon cancer between 1996 and 2003. Medical notes were reviewed, and surgical and oncology treatments were compared by indigenous status.RESULTS: Maori and non‐Maori patients had similar rates of surgical resection, although Maori patients were less likely to undergo extensive lymph node clearance and were more likely to die during the postoperative period. Maori patients were significantly less likely to receive chemotherapy for stage III disease (relative risk [RR], 0.69; 95% confidence interval [CI], 0.53‐0.91) and were more likely to experience a delay of at least 8 weeks before starting chemotherapy (RR, 1.98; 95%CI, 1.23‐3.16). Treatment disparities were not explained by differences in tumor characteristics or patient comorbidity.CONCLUSIONS: Maori New Zealanders with colon cancer were less likely to receive adjuvant chemotherapy and experienced a lower quality of care compared with non‐Maori patients. The authors concluded that attention to health system factors is needed to ensure equal access and quality of cancer treatment for indigenous and ethnic minority populations. Cancer 2010. © 2010 American Cancer Society.